A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer

NCT07082920 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

140

Enrollment

INDUSTRY

Sponsor class

Conditions

Prostatic Neoplasms

Interventions

DRUG: JNJ-78278343
DRUG: JNJ-95298177

Sponsor

Janssen Research & Development, LLC